Abbott

Q1 2021 FINANCIAL RESULTS

LIFE-CHANGING TECHNOLOGIES: FUELING TOP-TIER, SUSTAINED GROWTH

FIRST-QUARTER 2021 SALES WORLDWIDE

$10.5B in sales

+33%[1] on an organic basis*

SALES PERFORMANCE ACROSS ABBOTT[2]

ON AN ORGANIC BASIS*

- **+114.8%** DIAGNOSTICS
- **+8.8%** MEDICAL DEVICES
- **+6.4%** NUTRITION
- **+6.2%** ESTABLISHED PHARMACEUTICALS

FULL-YEAR 2021 GUIDANCE REMAINS UNCHANGED

ADJUSTED DILUTED EPS[3]

AT LEAST **$5.00**

REFLECTING GROWTH OF MORE THAN **35%** VERSUS PRIOR YEAR

GROWTH AND MOMENTUM ACROSS OUR PRODUCT PIPELINE

CARDIOVASCULAR



PIPELINE ADVANCES IN KEY SEGMENTS

- Strong growth in Structural Heart, Rhythm Management and Electrophysiology
- Expanded reimbursement for MitraClip®
- CE Mark for next-gen TriClip™ device

DIABETES CARE

STRONG GROWTH, GLOBAL LEADERSHIP

- Diabetes Care grew 24%[4] this quarter
- FreeStyle® Libre† system now has 3+ million users worldwide

DIAGNOSTICS

NEW BREAKTHROUGHS IN COVID-19 TESTING

- FDA EUA for over-the-counter BinaxNOW™ COVID-19 Self Test‡ shipping to retailers across the U.S. this week
- FDA EUA for Alinity™ m Resp-4-Plex§ molecular assay to detect and differentiate SARS-CoV-2, influenza A/B and RSV
- Provided nearly 700 million COVID-19 tests since the start of the pandemic

*Organic sales growth excludes impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated April 20, 2021, available at www.abbottinvestor.com.

† Find important safety information about the FreeStyle® Libre portfolio: www.freestylelibre.us/safety-information.

‡ The BinaxNOW™ COVID-19 Antigen Self Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19 infection when tested twice over three days with at least 36 hours between tests. This test is authorized for non-prescription home use with self-collected direct anterior nasal (nares) swab samples from individuals aged 15 years or older or adult collected anterior nasal swab samples from individuals aged two years or older.

The BinaxNOW COVID-19 Ag tests have not been FDA cleared or approved. They have been authorized by the FDA under an emergency use authorization. The tests have been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

§ The Abbott Alinity m Resp-4-Plex product has not been FDA cleared or approved, but been authorized for emergency use by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection and differentiation of nucleic acid from SARS-CoV-2, influenza A, influenza B, and/or Respiratory Syncytial Virus, not for any other viruses or pathogens; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

1. On a GAAP basis, first-quarter Abbott sales increased 35%. **2.** On a GAAP basis, Diagnostics sales increased 199.8%; Medical Devices sales increased 13.1%; Nutrition sales increased 6.9%; Established Pharmaceuticals sales increased 2.5%. **3.** Abbott projects full-year 2021 diluted earnings per share from continuing operations under GAAP of at least $3.74, reflecting growth of at least 50% versus the prior year. Abbott forecasts specified items for the full-year 2021 of $1.26 primarily related to intangible amortization, expenses associated with acquisitions, restructuring and cost reduction initiatives and other net expenses. **4.** On a GAAP basis, Diabetes Care increased 30%.

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.